Israel accuses Canadian medical cannabis of dumping
Published
Two Israeli medical cannabis producers, Trichom and Evergreen Solomon Pharma, are renewing their accusations against imports from Canada. According to them, these low-priced products are competing unfairly with local production.
The two companies say that these low-priced imports have harmed the cannabis industry in Israel. "Dumping" refers to a business practice in which a product is sold at a price below its real cost or below its price on the domestic market, in order to win market share. The Israeli producers therefore argue that the competition is not fair.
Medical cannabis is legal in several countries, including Israel and Canada, where it is used to treat certain illnesses under medical supervision. This market is growing rapidly around the world, which explains the producers' interest in international trade.
The case is not yet settled, and the authorities concerned have not, at this stage, made any public decision on these accusations. For French readers, this story remains an item of international news, but it helps us better understand the economic tensions that come with the development of medical cannabis around the world.
Sources: Newsweed
More France news
- Politics: after defeat, should you keep going or leave?
- Thomas Guénolé analyses the high school student movement, the police and Emmanuel Macron's politics
- A year on Mars without leaving Earth: NASA tests a simulated mission with four volunteers
- The French Chamber of Commerce in Malaysia celebrates 35 years of economic cooperation with Malaysia
- Good Morning Business: the Tuesday 17 November 2026 programme on BFM Business
- In Finistère, Maëlys Droal creates Maygnétic, a business club for women entrepreneurs
- Massay, a small club, qualifies for the next round of the Coupe de France
- The 1979 French champions return to Grünberg, where their title was prepared